Extranodal NK/T cell lymphoma, nasal type (ENKL), is a rare type of non-Hodgkin's lymphoma derived from natural killer (NK) cells in most cases and is closely associated with EBV. 1 Nasal ENKL of limited stage has a relatively good prognosis when treated with high-dose radiotherapy with chemotherapy; however, in refractory or relapsed cases, the prognosis is dismal. 2 Allogeneic hematopoietic cell transplantation (HCT) has been performed for a limited number of cases of ENKL, which led to a cure in some. 3 Graft-vs-lymphoma (GVL) effects are possible in these cases, although anti-lymphoma effects of drugs or irradiation in the conditioning regimens are not excluded.
We describe a patient with ENKL who relapsed after allogeneic HCT and had a durable response to donor lymphocyte infusions (DLI), clearly showing a GVL effect. A 29-year-old Japanese man was admitted to our hospital because of recurrent ENKL. He had had a history of chronic sinusitis for 3 years. A biopsy of a left nasal tumor had been performed 6 months earlier. He was diagnosed with ENKL from the histologically characteristic morphology with positivity for cytoplasmic CD3 epsilon, CD56 and EBV. His clinical stage was IIE of the Ann Arbor classification, and he received radiotherapy at 50 Gy and consecutive CHOP therapy for a total of three courses. He showed a partial response; then a high fever and a right facial palsy developed. He was diagnosed with recurrence of ENKL in the right parotid gland by biopsy and referred to us for further therapies.
After admission, restaging also revealed a duodenal infiltration by lymphoma. Salvage chemotherapy with a combination of paraplatin, etoposide, ifosphamide, and dexamethasone (DeVIC) was given with a partial response. He then received an allogeneic BMT from an HLAmatched brother, conditioned with 12 Gy of TBI and CY at 120 mg/kg. The numbers of infused cells and CD34-positive cells were 31 Â 10 7 /kg and 25.7 Â 10 5 /kg, respectively. GVHD prophylaxis was with CsA and short-term MTX. Neutrophil engraftment was achieved on day 13. Acute GVHD did not occur. The EBV viral load (VL) in the peripheral blood was under 10 copies/microgram DNA (copies), but was 1670 copies before allogeneic HCT.
On day 45, thickening of the left nasal mucosa was noticed and a biopsy from the lesion confirmed recurrence of ENKL, with EBV VL at 2500 copies. CsA was rapidly decreased and additional irradiation to the nasal area was given. Although a transient response was seen, the lymphoma recurred at multiple sites (Figure 1a) . Additional DeVIC therapy was not effective. A course of combined chemotherapy of Ara-C (120 mg/m 2 , on days 1-3), ifosphamide (1800 mg/m 2 , on days 1-3), MTX (3 g/m 2 , on day 5 with leucovorin rescue) and L-asparaginase (6000 IU/m 2 , days 9-12) was given from day 138. There was a transient response with decrease of EBV-VL; however, after recovery of BM suppression, reelevation of EBV-VL occurred. The patient refused further chemotherapy. Thereafter, DLI from the donor at a dose of 17.9 Â 10 6 CD3-positive cells/kg on day 174 was given. There had been a gradual decrease of EBV-VL from 9000 to 2420 copies, then to less than 100 copies and improvements in clinical symptoms. Complete response occurred 3 months later (Figure 1b) . The patient has now been well for 4 years with a complete response complicated by chronic GVHD of skin and liver.
A graft-vs-NK-cell lymphoma effect has been proposed in ENKL, as CR has been achieved after allogeneic HCT following myeloablative or non-myeloablative conditioning regimen in patients with refractory disease or partial response. 4 Planned DLIs after allogeneic HCT were also given in selected cases, 5, 6 which led to long-term CR. Multiple factors, such as conditioning regimen or the timing of immune modulations including DLI and immunosuppressant cessation, make it difficult to interpret any actual GVL effect. A recent report of a sustained response of ENKL lesions on withdrawal of immunosuppression upon relapse after allogeneic HCT also strongly suggests a GVL effect in ENKL. 7 However, therapeutic DLI for ENKL has not yet been evaluated.
In the present case, a single course of L-asparaginasecontaining chemotherapy and subsequent DLI for histologically proven, ENKL relapsing after allogeneic HCT induced CR with consequent chronic GVHD. Although L-asparaginase has been shown to play a significant role in the management of NK-cell malignancies, 8 it is very unlikely that CR in this case was attributable solely to the short course of chemotherapy given for relapse after allogeneic HCT with myeloablative conditioning; DLI had a major impact on this patient's disease response. This case highlights a potent GVL effect in ENKL treatment. Further studies are required to evaluate the exact roles and indications of therapeutic DLI for ENKL subjects. 9 
Conflict of interest
The authors declare no conflict of interest. 
